Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

This phase 1/2 study is the first prospective evaluation of lenalidomide-bortezomib-dexamethasone in front-line myeloma. Patients (N = 66) received 3-week cycles (n = 8) of bortezomib 1.0 or 1.3 mg/m(2) (days 1, 4, 8, 11), lenalidomide 15 to 25 mg (days 1-14), and dexamethasone 40 or 20 mg (days 1,...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Richardson, Paul G., Weller, Edie, Lonial, Sagar, Jakubowiak, Andrzej J., Jagannath, Sundar, Raje, Noopur S., Avigan, David E., Xie, Wanling, Ghobrial, Irene M., Schlossman, Robert L., Mazumder, Amitabha, Munshi, Nikhil C., Vesole, David H., Joyce, Robin, Kaufman, Jonathan L., Doss, Deborah, Warren, Diane L., Lunde, Laura E., Kaster, Sarah, DeLaney, Carol, Hideshima, Teru, Mitsiades, Constantine S., Knight, Robert, Esseltine, Dixie-Lee, Anderson, Kenneth C.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2010
Témata:
Plenary Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3324254/
https://ncbi.nlm.nih.gov/pubmed/20385792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-02-268862
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky